Skip to main content
Erschienen in: Diabetologia 10/2004

01.10.2004 | Article

A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)

verfasst von: P. M. Clarke, A. M. Gray, A. Briggs, A. J. Farmer, P. Fenn, R. J. Stevens, D. R. Matthews, I. M. Stratton, R. R. Holman, on behalf of the UK Prospective Diabetes Study (UKPDS) Group

Erschienen in: Diabetologia | Ausgabe 10/2004

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The aim of this study was to develop a simulation model for Type 2 diabetes that can be used to estimate the likely occurrence of major diabetes-related complications over a lifetime, in order to calculate health economic outcomes such as quality-adjusted life expectancy.

Methods

Equations for forecasting the occurrence of seven diabetes-related complications and death were estimated using data on 3642 patients from the United Kingdom Prospective Diabetes Study (UKPDS). After examining the internal validity, the UKPDS Outcomes Model was used to simulate the mean difference in expected quality-adjusted life years between the UKPDS regimens of intensive and conventional blood glucose control.

Results

The model’s forecasts fell within the 95% confidence interval for the occurrence of observed events during the UKPDS follow-up period. When the model was used to simulate event history over patients’ lifetimes, those treated with a regimen of conventional glucose control could expect 16.35 undiscounted quality-adjusted life years, and those receiving treatment with intensive glucose control could expect 16.62 quality-adjusted life years, a difference of 0.27 (95% CI: −0.48 to 1.03).

Conclusions/interpretations

The UKPDS Outcomes Model is able to simulate event histories that closely match observed outcomes in the UKPDS and that can be extrapolated over patients’ lifetimes. Its validity in estimating outcomes in other groups of patients, however, remains to be evaluated. The model allows simulation of a range of long-term outcomes, which should assist in informing future economic evaluations of interventions in Type 2 diabetes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Eastman RC, Javitt JC, Herman WH et al. (1997) Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 20:725–734PubMed Eastman RC, Javitt JC, Herman WH et al. (1997) Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 20:725–734PubMed
2.
Zurück zum Zitat Brown JB, Russell A, Chan W, Pedula K, Aickin M (2000) The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 50 [Suppl 3]:S15–S46 Brown JB, Russell A, Chan W, Pedula K, Aickin M (2000) The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 50 [Suppl 3]:S15–S46
3.
Zurück zum Zitat Palmer AJ, Brandt A, Valerio G, Weiss C, Stock H, Wenzel H (2000) Outline of a diabetes disease management model. Principles and applications. Diabetes Res Clin Pract 50 [Suppl 3]:S47–S56 Palmer AJ, Brandt A, Valerio G, Weiss C, Stock H, Wenzel H (2000) Outline of a diabetes disease management model. Principles and applications. Diabetes Res Clin Pract 50 [Suppl 3]:S47–S56
4.
Zurück zum Zitat Bagust A, Hopkinson PK, Maier W, Currie CJ (2001) An economic model of the long-term health care burden of Type II diabetes. Diabetologia 44:2140–2155CrossRefPubMed Bagust A, Hopkinson PK, Maier W, Currie CJ (2001) An economic model of the long-term health care burden of Type II diabetes. Diabetologia 44:2140–2155CrossRefPubMed
5.
Zurück zum Zitat CDC Group (2002) Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287:2542–2551PubMed CDC Group (2002) Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287:2542–2551PubMed
6.
Zurück zum Zitat DCCT (1996) Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. JAMA 276:1409–1415PubMed DCCT (1996) Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. JAMA 276:1409–1415PubMed
7.
Zurück zum Zitat Yeo WW, Yeo KR (2001) Predicting CHD risk in patients with diabetes mellitus. Diabet Med 18:341–344CrossRefPubMed Yeo WW, Yeo KR (2001) Predicting CHD risk in patients with diabetes mellitus. Diabet Med 18:341–344CrossRefPubMed
8.
Zurück zum Zitat UKPDS Group (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412CrossRefPubMed UKPDS Group (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412CrossRefPubMed
9.
Zurück zum Zitat Adler AI, Stratton IM, Neil HA et al. (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412–419CrossRefPubMed Adler AI, Stratton IM, Neil HA et al. (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412–419CrossRefPubMed
10.
Zurück zum Zitat Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 101:671–679CrossRef Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 101:671–679CrossRef
11.
Zurück zum Zitat Kothari V, Stevens RJ, Adler AI et al. (2002) UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33:1776–1781CrossRefPubMed Kothari V, Stevens RJ, Adler AI et al. (2002) UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33:1776–1781CrossRefPubMed
12.
Zurück zum Zitat UKPDS Group (1991) UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia 34:877–890PubMed UKPDS Group (1991) UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia 34:877–890PubMed
13.
Zurück zum Zitat UKPDS Group (1994) Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11:534–544PubMed UKPDS Group (1994) Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11:534–544PubMed
14.
Zurück zum Zitat Hougaard P (2000) Analysis of multivariate survival data (Statistics for biology and health). Springer, Berlin Hougaard P (2000) Analysis of multivariate survival data (Statistics for biology and health). Springer, Berlin
15.
Zurück zum Zitat American Diabetes Association (1998) Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 21:296–309PubMed American Diabetes Association (1998) Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 21:296–309PubMed
16.
Zurück zum Zitat Brown JB, Pedula KL, Bakst AW (1999) The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 159:1873–1880CrossRefPubMed Brown JB, Pedula KL, Bakst AW (1999) The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 159:1873–1880CrossRefPubMed
17.
Zurück zum Zitat Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB (1991) Probability of stroke: a risk profile from the Framingham Study. Stroke 22:312–318PubMed Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB (1991) Probability of stroke: a risk profile from the Framingham Study. Stroke 22:312–318PubMed
18.
Zurück zum Zitat Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG (1999) A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study. Diabetes Care 22:1036–1042PubMed Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG (1999) A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study. Diabetes Care 22:1036–1042PubMed
19.
Zurück zum Zitat Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ (1997) Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 278:2069–2074CrossRefPubMed Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ (1997) Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 278:2069–2074CrossRefPubMed
20.
Zurück zum Zitat UKPDS Group (2003) Development and progression of nephropathy in Type 2 diabetes: observation and modelling from the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225–232CrossRefPubMed UKPDS Group (2003) Development and progression of nephropathy in Type 2 diabetes: observation and modelling from the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225–232CrossRefPubMed
21.
Zurück zum Zitat Cupples LA, D’Agostino RB, Anderson K, Kannel WB (1988) Comparison of baseline and repeated measure covariate techniques in the Framingham Heart Study. Stat Med 7:205–222PubMed Cupples LA, D’Agostino RB, Anderson K, Kannel WB (1988) Comparison of baseline and repeated measure covariate techniques in the Framingham Heart Study. Stat Med 7:205–222PubMed
22.
Zurück zum Zitat Altman DG, De Stavola BL (1994) Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med 13:301–341PubMed Altman DG, De Stavola BL (1994) Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med 13:301–341PubMed
23.
Zurück zum Zitat Greene WH (1997) Econometric analysis, 4 edn. Prentice-Hall, London Greene WH (1997) Econometric analysis, 4 edn. Prentice-Hall, London
24.
Zurück zum Zitat UKPDS Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRefPubMed UKPDS Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRefPubMed
25.
Zurück zum Zitat Panzram G (1987) Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30:123–131PubMed Panzram G (1987) Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30:123–131PubMed
26.
Zurück zum Zitat Wright JC, Weinstein MC (1998) Gains in life expectancy from medical interventions—standardizing data on outcomes. N Engl J Med 339:380–386CrossRefPubMed Wright JC, Weinstein MC (1998) Gains in life expectancy from medical interventions—standardizing data on outcomes. N Engl J Med 339:380–386CrossRefPubMed
27.
Zurück zum Zitat EuroQol Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRefPubMed EuroQol Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRefPubMed
28.
Zurück zum Zitat Clarke P, Gray A, Holman R (2002) Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 22:340–349CrossRefPubMed Clarke P, Gray A, Holman R (2002) Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 22:340–349CrossRefPubMed
29.
Zurück zum Zitat Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19:453–473CrossRefPubMed Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19:453–473CrossRefPubMed
30.
Zurück zum Zitat Gray A, Raikou M, McGuire A et al. (2000) Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 320:1373–1378CrossRefPubMed Gray A, Raikou M, McGuire A et al. (2000) Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 320:1373–1378CrossRefPubMed
32.
Zurück zum Zitat Government Actuary’s Department (2003) Interim life tables 1999–2001. The Stationery Office, London Government Actuary’s Department (2003) Interim life tables 1999–2001. The Stationery Office, London
33.
Zurück zum Zitat Williams R, Van Gaal L, Lucioni C (2002) Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 45:S13–S17CrossRefPubMed Williams R, Van Gaal L, Lucioni C (2002) Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 45:S13–S17CrossRefPubMed
34.
Zurück zum Zitat Anderson KM, Odell PM, Wilson PW, Kannel WB (1991) Cardiovascular disease risk profiles. Am Heart J 121:293–298CrossRefPubMed Anderson KM, Odell PM, Wilson PW, Kannel WB (1991) Cardiovascular disease risk profiles. Am Heart J 121:293–298CrossRefPubMed
35.
Zurück zum Zitat Menotti A, Lanti M, Puddu PE (2000) Long-term time-related predictivity of coronary events as a function of a single measurement of serum cholesterol and systolic blood pressure. Acta Cardiol 55:87–93PubMed Menotti A, Lanti M, Puddu PE (2000) Long-term time-related predictivity of coronary events as a function of a single measurement of serum cholesterol and systolic blood pressure. Acta Cardiol 55:87–93PubMed
36.
Zurück zum Zitat Stevens R, Adler A, Gray A, Briggs A, Holman R (2000) Life-expectancy projection by modelling and computer simulation (UKPDS 46). Diabetes Res Clin Pract 50 [Suppl 3]:S5–S13 Stevens R, Adler A, Gray A, Briggs A, Holman R (2000) Life-expectancy projection by modelling and computer simulation (UKPDS 46). Diabetes Res Clin Pract 50 [Suppl 3]:S5–S13
Metadaten
Titel
A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)
verfasst von
P. M. Clarke
A. M. Gray
A. Briggs
A. J. Farmer
P. Fenn
R. J. Stevens
D. R. Matthews
I. M. Stratton
R. R. Holman
on behalf of the UK Prospective Diabetes Study (UKPDS) Group
Publikationsdatum
01.10.2004
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 10/2004
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1527-z

Weitere Artikel der Ausgabe 10/2004

Diabetologia 10/2004 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.